Biomarkers of response to ocrelizumab in relapsing–remitting multiple sclerosis
ObjectiveTo ascertain the changes of serum neurofilament light chain (sNfL) and glial fibrillary acidic protein (sGFAP) values in relapsing–remitting multiple sclerosis (RRMS) patients treated with ocrelizumab and their association with treatment response.MethodsMulticenter prospective study includi...
Saved in:
Similar Items
-
Corrigendum: Biomarkers of response to ocrelizumab in relapsing–remitting multiple sclerosis
by: Fernando Rodríguez-Jorge, et al.
Published: (2024-12-01) -
20403. NIVELES SÉRICOS DE NEUROFILAMENTOS DE CADENA LIGERA COMO FACTOR PREDICTOR DE RESPUESTA EN UNA COHORTE MULTICÉNTRICA DE PACIENTES CON ESCLEROSIS MÚLTIPLE TRATADOS CON OCRELIZUMAB
by: F. Rodríguez Jorge, et al.
Published: (2024-11-01) -
Ocrelizumab-induced colitis—critical review and case series from a Romanian cohort of MS patients
by: Ileana Maria Vodă, et al.
Published: (2025-02-01) -
From pathogenesis to new developments in treatment of primary progressive multiple sclerosis. Literature review
by: A. Juknelytė, et al.
Published: (2020-03-01) -
20178. LA VELOCIDAD DE TECLEO OBTENIDA DURANTE EL PRIMER MES ES PREDICTIVA DE LA PROGRESIÓN INDEPENDIENTE DE BROTES EN PACIENTES CON ESCLEROSIS MÚLTIPLE
by: J. Chico García, et al.
Published: (2024-11-01)